These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 916498)

  • 21. [Modification during treatment of the rate of acetylation of isoniazide clinically or biologically detectable hepatic damage (author's transl)].
    Albengres E; Houin G; Breau JL; Hirsch A; Saltiel JC; Tillement JP; Chrétien J
    Nouv Presse Med; 1977 Oct; 6(32):2869-71. PubMed ID: 917803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical tolerance of rifampycin administered alone or in combination with other antitubercular drugs].
    Carratù L; Sonaglioni F; Natali P
    Arch Tisiol Mal Appar Respir; 1968 May; 23(5):399-410. PubMed ID: 5306592
    [No Abstract]   [Full Text] [Related]  

  • 23. [Complex hospital treatment of pulmonary tuberculosis].
    Bondarev IM; Batmanov NIa; Shesterina MV; Gavrilenko VS; Tarasova EF
    Sov Med; 1980; (6):79-82. PubMed ID: 6998023
    [No Abstract]   [Full Text] [Related]  

  • 24. Adult tuberculous meningitis: comparative study of different chemotherapeutic regimens.
    Acharya VN; Kudva BT; Retnam VJ; Mehta PJ
    J Assoc Physicians India; 1985 Sep; 33(9):583-5. PubMed ID: 4093404
    [No Abstract]   [Full Text] [Related]  

  • 25. [Proceedings: Tuberculosis therapy. Review on today's knowledge, developmental trends and still open problems].
    Eule H; Krebs A; Iwainsky H
    Z Erkr Atmungsorgane Folia Bronchol; 1973; 138(1):78-100. PubMed ID: 4131870
    [No Abstract]   [Full Text] [Related]  

  • 26. Incidence of resistance to primary and secondary antituberculosis drugs in isolates of M. tuberculosis from cases of pulmonary tuberculosis.
    Kothadia SN; Sengupta SR
    Indian J Chest Dis Allied Sci; 1984; 26(3):163-6. PubMed ID: 6443608
    [No Abstract]   [Full Text] [Related]  

  • 27. [Clinical significance of antitubercular agents and protein binding].
    Aoyagi A
    Kekkaku; 1977 Mar; 52(3):101-3. PubMed ID: 859236
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of laryngeal tuberculosis (author's transl)].
    Gastpar H
    Z Laryngol Rhinol Otol; 1973 Aug; 52(8):604-8. PubMed ID: 4741792
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic problems in the management of elderly patients with tuberculosis.
    Woo J; Chan HS
    Adverse Drug React Toxicol Rev; 1992; 11(1):13-8. PubMed ID: 1606279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical pharmacology of pentazocine-diazepam anesthesia. 2. Protein binding and pharmacokinetics of diazepam (author's transl)].
    Yamamoto K; Murakami S; Tsuji A
    Masui; 1980 Oct; 29(10):1013-9. PubMed ID: 7452900
    [No Abstract]   [Full Text] [Related]  

  • 32. Augmentation of hepatic uridine-diphosphate glucuronyl transferase activity by antituberculous drugs in hamsters in vivo.
    Constantopoulos A; Loupa H; Krikos X
    Cytobios; 1987; 52(210-211):185-91. PubMed ID: 3123148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of tuberculous praevesical ureteral strictures (author's transl)].
    May P; Schindler E
    Urologe A; 1974 Jan; 13(1):1-5. PubMed ID: 4856813
    [No Abstract]   [Full Text] [Related]  

  • 34. [Side effects of antituberculous drugs observed within six months after admission. Tuberculosis Research Committee, Ryoken (author's transl)].
    Kekkaku; 1975 Jun; 50(6):161-7. PubMed ID: 1185917
    [No Abstract]   [Full Text] [Related]  

  • 35. [Histological characteristics of tuberculous cavity treated with rifampicin--a comparative study with cases treated by primary drugs (author's transl)].
    Tanaka I; Iwai K
    Kekkaku; 1981 Jul; 56(7):355-60. PubMed ID: 7328996
    [No Abstract]   [Full Text] [Related]  

  • 36. [Sensitivities of atypical mycobacteria to various drugs. I. Sensitivities to antituberculous drugs (author's transl)].
    Kuze F; Takeda S; Maekawa N
    Kekkaku; 1974 Jun; 49(6):151-6. PubMed ID: 4410839
    [No Abstract]   [Full Text] [Related]  

  • 37. [Pharmacokinetic parameters in relation to structure of the N-pycolyl-3,5-dimethylbenzamides (author's transl)].
    Idoipe Tomás A
    Arch Farmacol Toxicol; 1977 Aug; 3(2):141-56. PubMed ID: 921335
    [No Abstract]   [Full Text] [Related]  

  • 38. [Protein binding of sulphachlorpiridacine (author's transl)].
    Mariño EL; Tabernero JM; Macías JG; Domínguez-Gil A; de Castro S
    Arch Farmacol Toxicol; 1979 Aug; 5(2):107-16. PubMed ID: 533316
    [No Abstract]   [Full Text] [Related]  

  • 39. [Study of the binding between uric acid and plasma proteins (author's transl)].
    Sforza GR; Marcolongo R; Della Fazia L; Masciangelo F; Morozzi G; Lo Cosmo C
    Quad Sclavo Diagn; 1980 Dec; 15(4):1075-89. PubMed ID: 7454962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assessment of the serum binding capacity for bromsulphtalein on the principle of dialysis (author's transl)].
    Buncová M; Horký J
    Cesk Gastroenterol Vyz; 1976 Sep; 30(6):352-7. PubMed ID: 1000651
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.